Product Images Donepezil Hydrochloride

The text seems to be a graph displaying the change from baseline in ADCS-ADL score with Donepezil Hydrochloride 10 mg/day and placebo, over 3 and 6 months of drug treatment. It is showing the mean values and standard error (SE) for both treatment groups. The graph indicates that there was clinical improvement in the ADCS-ADL score in the Donepezil Hydrochloride group compared to placebo.*

This appears to be a graph showing the Cumulative Percentage of Patients for Donepezil Hydrochloride 10mg/day and Placebo, with the x-axis showing the ADCS-ADL Change from Baseline and the y-axis showing the percentage of patients. Not enough information is provided to interpret the graph beyond this.*

This text presents a chart showing the effects of Donepezil Hydrochloride at different dosages on the clinical improvement and decline of patients over a 24-week period. The chart compares the effects of treatment with 23 mg/day and 10 mg/day dosages of the drug, and measures the clinical improvement or decline of the patients over the course of the drug treatment. No other details or context is available.*

This appears to be a chart showing the percentage of patients who underwent treatment with two different doses of Donepezil Hydrochloride (either 10 mg/day or 23 mg/day) and their corresponding improvements according to the CIBIC-plus rating scale. The scale ranges from "Markedly Improved" to "Markedly Worse".*

This appears to be a chart or graph showing the ADAS-cog Change from Baseline in patients receiving different dosages of Donepezil Hydrochloride and Placebo over a period of 30 weeks of drug treatment. The x-axis shows the duration in weeks and the y-axis shows the scores ranging from -2 to 2. There are three lines representing Clinical Improvement, Placebo, and the two different dosages of Donepezil Hydrochloride (10mg/day and 5mg/day). The baseline is marked at 0, and the graph shows the change in ADAS-cog scores over time.*

This is a description of a study comparing the effects of Donepezil Hydrochloride (10mg and 5mg) with Placebo on the cognitive function of patients, as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). The table shows the cumulative percentage of patients in treatment and placebo groups who experienced no change, as well as improvements (4/7 points) or worsening (7 points) of condition over a certain period of time. The results suggest that Donepezil Hydrochloride (both doses) is more effective than the Placebo in improving cognitive function.*

This appears to be a data table showing the percentages of patients who received a certain dosage of Donepezil Hydrochloride and the resulting improvement or worsening of their condition according to the CIBIC-plus Rating. The table also includes a placebo group.*

This is a table showing the change in ADAS-cog (a score that measures cognitive function in Alzheimer's disease) for patients taking different doses of Donepezil Hydrochloride and placebo, along with the cumulative percentage of patients who experienced a certain level of improvement or decline in cognitive function. The table suggests that higher doses of Donepezil Hydrochloride (5 mg/day and 10 mg/day) led to greater improvement in cognitive function compared to placebo and lower doses of the medication.*